Key Drivers
- Strong balance sheet
- Strong cash flow
- Rich valuation
AIAI Summary
HRMY now looks more like a durable cash-generating franchise than a speculative specialty-pharma story, with Q2 confirming WAKIX momentum, strong margins, and ample cash, but the stock still hinges on how long that single-product engine can compound before pipeline assets meaningfully diversify revenue—making concentration and patent/legal risk the main things to watch.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong balance sheet
- •Strong cash flow
- •Rich valuation
HRMY stands out for its strong balance sheet, high margins, and excellent cash generation, but the stock is now less compelling after a rerating and still carries a heavy expense load.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Resistance test
- •Stretched rally
HRMY remains in a short-term uptrend with higher highs/lows, but the pullback from its last-month high near $39.8 shows near-term resistance and suggests a pause unless it reclaims $39.8, with support at $38.0-$38.4 and stronger support at $35.2-$35.9.
Fast advance from the mid-$33s to near $40 suggests short-term overextension
Sentiment & News
Key News Insights:
- •Wakix recovery
- •Guidance reaffirmed
- •Pipeline expansion
Harmony Biosciences delivered a strong Q2 beat on Wakix-driven revenue growth and raised investor confidence by reaffirming 2026 guidance while highlighting pipeline progress beyond its core franchise.
The news is mildly positive for HRMY, reinforcing momentum in the core business and supporting the case for continued upside if execution and pipeline progress hold
Similar Companies in Healthcare
Other companies in the same sector with AI ratings